/
DCF Valuation
Base-case fair value
$79.62
Intrinsic $106.17 · 25% MOS
Current price: $54.21
Base-case summary
Our base-case DCF for Kiniksa Pharmaceuticals International, plc (KNSA) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 131.7% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $164M in trailing free cash flow, this produces an intrinsic value of $106.17 per share. A 25% safety margin gives a fair value of $79.62, suggesting the stock is currently 47% undervalued against the $54.21 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$164M
Cash & equivalents
$468M
Total debt
$9M
Shares outstanding
82M